At the HonorHealth Research Institute, patients have access to tomorrow’s cure today. In existence since 2005, the institute focuses on creating innovative medical advances for today’s most pressing health concerns. We currently have several clinical trials available for patients who have been diagnosed with pancreatic cancer and are interested in clinical trials as an additional treatment option.

• Open-label, phase II study in patients with resectable and borderline resectable pancreatic cancer – this trial is for individuals with localized pancreatic cancer. It involves utilizing the genomic result of their biopsy to select their best initial therapy. Learn more about the study and eligibility criteria
• A study for individuals with metastatic pancreatic cancer. It involves CM24 in combination with Nivolumab in adults with advanced pancreatic cancer, chemotherapy and immune therapy second line trial. Learn more about the study and eligibility criteria
• Advanced Pancreatic Cancer trial for refractory advanced pancreatic cancer utilizing an agent that targets the tumor microenvironment (TGFB) with one that stimulates the immune system (IL-15). Learn more about the study and eligibility criteria
• Clinical trial for patients with advanced pancreatic cancer with DNA repair mutations involving Lurbinectedin. Learn more about the study and eligibility criteria

For more information about these or other clinical trials at HonorHealth Research Institute, contact the institute at 480-323-1364 or 833-354-6667